ATYR vs. AMPH, ARDX, EVO, ETNB, OCUL, GPCR, IOVA, CALT, AUPH, and GYRE
Should you be buying Atyr PHARMA stock or one of its competitors? The main competitors of Atyr PHARMA include Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), Ocular Therapeutix (OCUL), Structure Therapeutics (GPCR), Iovance Biotherapeutics (IOVA), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.
Atyr PHARMA vs.
Atyr PHARMA (NASDAQ:ATYR) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.
61.7% of Atyr PHARMA shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Amphastar Pharmaceuticals had 5 more articles in the media than Atyr PHARMA. MarketBeat recorded 9 mentions for Amphastar Pharmaceuticals and 4 mentions for Atyr PHARMA. Amphastar Pharmaceuticals' average media sentiment score of 0.72 beat Atyr PHARMA's score of -0.03 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.
Atyr PHARMA has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
Amphastar Pharmaceuticals received 379 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 65.99% of users gave Amphastar Pharmaceuticals an outperform vote.
Amphastar Pharmaceuticals has higher revenue and earnings than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Atyr PHARMA currently has a consensus price target of $18.60, indicating a potential upside of 474.07%. Amphastar Pharmaceuticals has a consensus price target of $43.50, indicating a potential upside of 53.33%. Given Atyr PHARMA's stronger consensus rating and higher probable upside, equities analysts clearly believe Atyr PHARMA is more favorable than Amphastar Pharmaceuticals.
Amphastar Pharmaceuticals has a net margin of 21.80% compared to Atyr PHARMA's net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Atyr PHARMA's return on equity.
Summary
Amphastar Pharmaceuticals beats Atyr PHARMA on 12 of the 19 factors compared between the two stocks.
Get Atyr PHARMA News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atyr PHARMA Competitors List
Related Companies and Tools
This page (NASDAQ:ATYR) was last updated on 3/27/2025 by MarketBeat.com Staff
Buy ATYR Stock Free ATYR Stock Alerts